Switching RET Inhibitors Under an Unplanned Supply Disruption
Eight months into an excellent response, her RET inhibitor’s US commercialization is changing hands for reasons that have nothing to do with how well it is working, and continuity of supply is unconfirmed. The disagreement is whether switching a well-controlled patient for access reasons alone carries its own real risk.
Anna T., 58, retired from library work three years ago but kept volunteering weekly, reading picture books to a rotating group of preschoolers at the branch two blocks from her house — a routine she had to pause for the first time in twenty years when a persistent hoarseness and unexplained weight loss led, eight months ago, to a diagnosis of metastatic lung adenocarcinoma with a RET gene fusion on tissue testing, in a patient who had never smoked a cigarette in her life. Her staging workup at the time also found a single small adrenal lesion, later confirmed metastatic on biopsy, and a baseline echocardiogram read as normal apart from a QTc of 428 milliseconds, unremarkable then but relevant to what comes next. She started pralsetinib and, within two months, had a near-complete response on repeat imaging — the mediastinal mass essentially gone, two small liver lesions no longer visible — and was back reading to her preschoolers by month three, her only real side effect a modest rise in blood pressure now controlled on a single added medication.
That response is what makes today’s news land as hard as it does: pralsetinib’s original developer has exited its commercialization partnership for commercial, not safety or efficacy, reasons, and US rights are mid-transfer to a smaller acquiring company. The drug remains FDA-approved for exactly her indication and is not being withdrawn — but her specialty pharmacy cannot confirm uninterrupted supply through the handover, and marketing has already been discontinued outside the US, which is what has her oncologist treating a distribution gap as a live possibility rather than a remote one. Selpercatinib, approved for the same RET fusion on the strength of LIBRETTO-001’s own response and durability data, is the obvious replacement in principle — but switching a patient already deep into an excellent response on one RET inhibitor to a different one has essentially no direct outcome data behind it. ARROW and LIBRETTO-001 each studied their own drug in RET-inhibitor-naive and separately-treated populations; neither trial was built around this specific transition. Her baseline QTc, unremarkable when it was recorded eight months ago on a drug without a major QT signal, becomes a genuinely relevant number the moment selpercatinib enters the conversation, since selpercatinib carries its own labeled QT-prolongation warning that pralsetinib does not share to the same degree.
Planning a switch nobody wanted to make
Start the switch to selpercatinib now, while she is stable and well, rather than wait for the pralsetinib supply to actually run out. An uncontrolled interruption — whatever its length — caused by a specialty-pharmacy transfer or a stalled prior authorization is a real risk to a six-month remission, and it is entirely avoidable if we control the timing ourselves instead of letting an administrative deadline control it for us.
You are right that an uncontrolled gap in therapy is the actual danger here, not a planned one.
But switching her today, before we have even confirmed how much pralsetinib supply she actually still has, trades a hypothetical future risk for a real one right now: neither ARROW nor LIBRETTO-001 has any real data on converting a deep responder from one RET inhibitor to the other, and selpercatinib’s own adverse-effect profile — QT prolongation, transaminase elevation, hypertension of its own — is not simply more of the same drug she is already tolerating. Confirm the actual runway on her current supply before deciding whether this is urgent or has months to plan properly.
Both of you are right about different halves of the actual bottleneck. The clinical switch itself, drug to drug, is a same-day decision whenever we choose to make it — the real lag is administrative, not pharmacologic: a new prior authorization for selpercatinib can take two to four weeks to clear on its own, independent of anything about her disease.
So do both things in parallel rather than treating this as sequential: confirm her actual remaining pralsetinib supply today, and start the selpercatinib prior authorization today regardless of what that supply number turns out to be. Whichever runs out first, the drug or the paperwork, we want the other one already finished.
Agreed: confirm the actual remaining pralsetinib supply with the specialty pharmacy and start the selpercatinib prior authorization today, running both tracks in parallel; obtain a baseline ECG before any selpercatinib start given its QT-prolongation signal; switch when supply nears exhaustion or authorization clears, whichever comes later.
Not agreed: the Medical Oncologist still would have preferred switching within two weeks regardless of remaining supply, treating an earlier planned transition as the more conservative choice; the Oncology Pharmacist held that using the full remaining supply of a drug she is tolerating and responding to, rather than switching for a hypothetical future problem, is the more conservative reading. Both accepted the parallel-track compromise while disagreeing about which risk it actually hedges against more.